BACKGROUND: No study has so far addressed whether differences do exist in the management of cancer pain between patients receiving usual care by primary specialists and those receiving early palliative/supportive intervention. PATIENTS AND METHODS: A multicentre cross-sectional study in 32 Italian Hospitals has included 1450 patients, receiving analgesic therapy for cancer pain: 602 with access to primary specialist alone (standard care, SC) and 848 with early access to a palliative/supportive care (ePSC) team, concomitant with primary oncology care. RESULTS: Statistically significant differences in the analgesic drug administration according to care model have been evident: non-opioids were more frequently used in SC (9.5% versus 2%; P<0.001), while strong opioids in ePSC group (80% versus 63%; P<0.001). The number of patients with severe pain was lower in ePSC compared with SC group (31% versus 17%; P<0.001). Results of multivariate analysis have shown that ePSC integrated with primary oncologic care (relative risk 0.69; 95% confidence interval 0.48-0.99; P=0.045) was an independent factor associated with a 31% reduced risk of suffering from severe pain. CONCLUSIONS: An ePSC team provides the most effective standard of analgesic therapy for cancer pain. A randomized clinical trial is needed to confirm these findings.
BACKGROUND: No study has so far addressed whether differences do exist in the management of cancer pain between patients receiving usual care by primary specialists and those receiving early palliative/supportive intervention. PATIENTS AND METHODS: A multicentre cross-sectional study in 32 Italian Hospitals has included 1450 patients, receiving analgesic therapy for cancer pain: 602 with access to primary specialist alone (standard care, SC) and 848 with early access to a palliative/supportive care (ePSC) team, concomitant with primary oncology care. RESULTS: Statistically significant differences in the analgesic drug administration according to care model have been evident: non-opioids were more frequently used in SC (9.5% versus 2%; P<0.001), while strong opioids in ePSC group (80% versus 63%; P<0.001). The number of patients with severe pain was lower in ePSC compared with SC group (31% versus 17%; P<0.001). Results of multivariate analysis have shown that ePSC integrated with primary oncologic care (relative risk 0.69; 95% confidence interval 0.48-0.99; P=0.045) was an independent factor associated with a 31% reduced risk of suffering from severe pain. CONCLUSIONS: An ePSC team provides the most effective standard of analgesic therapy for cancer pain. A randomized clinical trial is needed to confirm these findings.
Authors: Stephen H Taplin; Sallie Weaver; Eduardo Salas; Veronica Chollette; Heather M Edwards; Suanna S Bruinooge; Michael P Kosty Journal: J Oncol Pract Date: 2015-04-14 Impact factor: 3.840
Authors: Enrico Vasile; Maurizio Lucchesi; Laura Ginocchi; Isa Maura Brunetti; Luca Galli; Sergio Ricci; Alfredo Falcone; Andrea Antonuzzo Journal: Support Care Cancer Date: 2014-01-05 Impact factor: 3.603
Authors: Ilene H Zuckerman; Amy J Davidoff; Mujde Z Erten; Bruce Stuart; Thomas Shaffer; J Samantha Dougherty; Candice Yong Journal: Support Care Cancer Date: 2014-08 Impact factor: 3.603
Authors: Richard A Taylor; Cardinale B Smith; Heather Coats; Laura P Gelfman; J Nicholas Dionne-Odom Journal: J Palliat Med Date: 2017-09-28 Impact factor: 2.947
Authors: Wiebke Jensen; Laura Bialy; Gesche Ketels; Freerk T Baumann; Carsten Bokemeyer; Karin Oechsle Journal: Support Care Cancer Date: 2013-12-07 Impact factor: 3.603